Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) were up 750,000% on Monday . The stock traded as high as $0.75 and last traded at $0.75. Approximately 225 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 3,042 shares. The stock had previously closed at $0.00.
Eloxx Pharmaceuticals Price Performance
The company’s 50 day moving average is $0.25.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
Featured Stories
- Five stocks we like better than Eloxx Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Finding Hidden Gems: Unconventional Penny Stock Investing
- What Are Dividends? Buy the Best Dividend Stocks
- Price Targets on NVIDIA Rise in Front of Earnings
- Retail Stocks Investing, Explained
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
